Ladenburg analyst Kevin Degeeter initiated coverage of Novocure (NVCR) with a Buy rating and $30 price target
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVCR:
- Promising Phase 3 Results for NovoCure’s TTFields Therapy in Pancreatic Cancer
- Novocure to present final secondary endpoint results from PANOVA-3 trial
- Novocure management to meet with Piper Sandler
- NovoCure Appoints New President at Annual Meeting
- Novocure data support pancreatic cancer approval, says Wells Fargo